Prof Michael Seckl: Why attend Future Horizons in Lung Cancer?

Editor's Choice for June 2016

Better screening programmes needed for haematological malignancies such as leukaemia

Pre-leukaemic clones that survive chemo linked to higher risk of AML recurrence

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity

Multi-target S-DNA increases colorectal cancer screening among previously non-compliant patients

Elucidation and pharmacological targeting of tumour checkpoint dependencies

Non-coding mutations driving chronic lymphocytic leukaemia

Next-generation sequencing in the lymphoid malignancies

WIN 2016: Preview of themes

WIN 2016: Preview of Speakers

Management of CLL patients in the front-line setting: live broadcast